ReJoin (human adipose-derived mesenchymal progenitor cells) / AbelZeta Pharma - LARVOL DELTA

A Clinical Study of Mesenchymal Progenitor Cell Exosomes Nebulizer for the Treatment of Pulmonary Infection (clinicaltrials.gov) - P1/2 | N=60 | Suspended | Sponsor: Ruijin Hospital | Trial completion date: Jul 2023 ➔ Mar 2025 | Recruiting ➔ Suspended | Trial primary completion date: May 2023 ➔ Dec 2024

Gram negative • Trial completion date • Trial primary completion date • Trial suspension • Infectious Disease • Respiratory Diseases

Three-dimensional texture analyses of multi-quantitative relaxation time maps for evaluating cartilage repair with the treatment of allogeneic human adipose-derived mesenchymal progenitor cells. (PubMed, Magn Reson Imaging) - "Texture analysis of the cartilage may allow the detection of compositional variation in cartilage repair with the treatment of allogeneic haMPCs. This technique displays potential applications in understanding the mechanism of stem cell repair of the cartilage and assessing the treatment response."

Journal • Immunology • Osteoarthritis • Pain • Rheumatology

A Clinical Study of Mesenchymal Progenitor Cell Exosomes Nebulizer for the Treatment of Pulmonary Infection (clinicaltrials.gov) - P1/2; N=60; Recruiting; Sponsor: Ruijin Hospital

Clinical • New P1/2 trial

CBMG Research & Development Update (Cellular Biomedicine Group Press Release) - "Re-join® Phase II Trial will be delayed to kick off in Q4 2020 due to COVID-19."

Trial initiation date • Osteoarthritis • Pain

Cellular Biomedicine Group reports Q1 2020 financial results and business highlights (PRNewswire) - "Regarding our regenerative medicine program, with the COVID-19 outbreak tapering off in China, we have resumed patients' enrollment for our knee osteoarthritis (KOA) Phase II allogenic (off the shelf AlloJoin®) stem-cell clinical trial and are in the process of preparing for the Phase II autologous (ReJoin®) trial as well."

Enrollment status • Trial status • CNS Disorders • Immunology • Inflammation • Osteoarthritis • Pain • Rheumatology

CBMG: Data from multiple myeloma trial to be presented at ASH… (Yahoo Finance) - "Cellular Biomedicine Group has also initiated a Phase 2 clinical trial in China for AlloJoin®, the company’s allogenic stem cell therapy for knee osteoarthritis, and China’s National Medical Products Administration (NMPA) has accepted the company’s planned Phase 2 trial for ReJoin®, the company’s autologous stem cell therapy for knee osteoarthritis."

New P2 trial • Non-US regulatory • Trial status

Cellular Biomedicine Group's ReJoin therapy receives stem cell drug application acceptance for phase II clinical trials by China NMPA (PRNewswire) - "Cellular Biomedicine Group, Inc....today announced that a drug application* for its off-the-shelf autologous adipose-derived mesenchymal progenitor cell (haMPC) ReJoin® therapy for Knee Osteoarthritis (KOA) has been accepted for a Phase II clinical trial in China."

New P2 trial • Non-US regulatory